Adicet is actively developing promising best-in-class therapies to treat hematological malignancies and solid tumors. The company is expanding its pipeline.
The Leadership and Board of Directors for Adicet Bio, a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.
Cookie Notice for the Adicet Bio website. Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.
Privacy Policy for the Adicet Bio website. Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.
Terms of Use for the Adicet Bio website. Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.
